Robert W. Baird Has Lowered Expectations for Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price

Enanta Pharmaceuticals (NASDAQ:ENTA) had its price objective cut by analysts at Robert W. Baird from $26.00 to $20.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Robert W. Baird’s price target would suggest a potential upside of 126.50% from the stock’s current price.

A number of other research analysts have also issued reports on ENTA. Evercore ISI upgraded shares of Enanta Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, August 6th. JPMorgan Chase & Co. reduced their price objective on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a report on Tuesday, August 6th. JMP Securities reissued a “market outperform” rating and set a $21.00 price target (down from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday. Finally, HC Wainwright reissued a “buy” rating and set a $27.00 price target on shares of Enanta Pharmaceuticals in a report on Thursday, October 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $19.50.

Enanta Pharmaceuticals Trading Up 3.2 %

NASDAQ:ENTA opened at $8.83 on Tuesday. The business’s fifty day moving average price is $10.92 and its 200 day moving average price is $12.30. The firm has a market capitalization of $187.11 million, a price-to-earnings ratio of -1.61 and a beta of 0.56. Enanta Pharmaceuticals has a 1-year low of $8.00 and a 1-year high of $17.80.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Rhumbline Advisers grew its stake in Enanta Pharmaceuticals by 4.7% during the second quarter. Rhumbline Advisers now owns 34,566 shares of the biotechnology company’s stock worth $448,000 after buying an additional 1,548 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in Enanta Pharmaceuticals in the 2nd quarter valued at approximately $35,000. US Bancorp DE increased its position in Enanta Pharmaceuticals by 4,933.7% during the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 4,243 shares during the period. State Board of Administration of Florida Retirement System acquired a new stake in Enanta Pharmaceuticals during the 1st quarter valued at approximately $118,000. Finally, American Century Companies Inc. grew its position in shares of Enanta Pharmaceuticals by 35.4% during the 2nd quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock worth $362,000 after buying an additional 7,287 shares during the period. 94.99% of the stock is currently owned by institutional investors and hedge funds.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.